Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Halaven (eribulin mesylate) is indicated for the treatment of metastatic breast cancer in patients who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease, with prior therapy including an anthracycline and a taxane in either the adjuvant or metastatic setting. It is also indicated for the treatment of unresectable or metastatic liposarcoma in patients who have received a prior anthracycline-containing regimen.
• This summary is based on the review of three systematic review(s)/meta-analysis(es). ^[1-3]
• Eribulin-based therapy demonstrated a significantly improved overall survival (OS) with a hazard ratio (HR) of 0.77 (95% CI: 0.67-0.88) compared to non-eribulin regimens, supported by subgroup analyses based on receptor expression and line of therapy.
• In second- or later-line treatments, eribulin was associated with longer OS compared to treatment by physician's choice (HR: 0.81; CrI: 0.66-0.99) and GEM+VIN (HR: 0.62; CrI: 0.42-0.90). Specifically, in triple-negative breast cancer (TNBC), eribulin showed improved OS compared to capecitabine (HR: 0.70; CrI: 0.54-0.90).
• Real-world evidence revealed variability in median OS, ranging from 6.9 to 28.0 months, with TNBC patients experiencing a median OS between 3.0 and 23.0 months.
• The incidence of all-grade neutropenia was significantly higher in the eribulin group compared to non-eribulin regimens.
• Specific adverse events were not detailed in the studies for comparisons with other chemotherapies.
• There is no population types or subgroups information available in the reviewed studies.